Importance of end-to-end QC processes for RNA biomarker discovery

Name: Importance of end-to-end QC processes for RNA biomarker discovery
Start: 2026-11-03
End: 2026-11-03

Starts: November 3, 2026
Ends: November 3, 2026
Format: Online
Location: VIRTUAL

About This Event

Cheryl Sesler, Associate Director of Research at Decode Health Inc., and Dr. Annika Dorn, Agilent Technologies, share how next-gen RNA seq enables the discovery of novel candidate biomarkers and addresses reproducibility challenges with a robust QC framework. Discover how the Agilent TapeStation system can be used to ensure reliable QC in RNA-seq workflows and support disease-agnostic biomarker discovery.